To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment
Sponsor: AstraZeneca
Listed as NCT03060512, this PHASE4 trial focuses on Opioid Induced Constipation and remains completed. Sponsored by AstraZeneca, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE4
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE4
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Mar 2017 — Jul 2017 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- QuintilesIMS, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .